argenx Balance Sheet Health
Financial Health criteria checks 5/6
argenx has a total shareholder equity of $4.1B and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $4.5B and $445.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$3.18b |
| Equity | US$4.10b |
| Total liabilities | US$444.95m |
| Total assets | US$4.54b |
Recent financial health updates
No updates
Recent updates
argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Feb 01Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod
Sep 21Argenx's neuromuscular disorder drug Vyvgart wins approval in EU
Aug 11Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M
Jul 28argenx: A Very Good Start For Vyvgart
May 25argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain
May 18argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers
Mar 07argenx: Vyvgart's Approval A Key Step For Continued Value Creation
Dec 22argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers
Nov 30argenx: R&D Day Goes Unnoticed
Aug 23argenx: Next Phase Of Growth With Efgartigimod And ARGX-117
Jun 30Argenx to regain global rights to cusatuzumab from Janssen Pharmaceuticals
Jun 07Argenx raises ~$1B in global offering
Feb 03argenx to raise $750M in proposed global offering
Feb 01argenx on target to file efgartigimod applications in Japan and Europe
Jan 08argenx and Zai Lab collaborate for Efgartigimod in Greater China
Jan 06Argenx inks $98M deal to secure accelared review status for efgartigimod
Nov 23argenx (ARGX) Investor Presentation - Slideshow
Nov 18Financial Position Analysis
Short Term Liabilities: ARGX's short term assets ($4.1B) exceed its short term liabilities ($423.0M).
Long Term Liabilities: ARGX's short term assets ($4.1B) exceed its long term liabilities ($22.0M).
Debt to Equity History and Analysis
Debt Level: ARGX is debt free.
Reducing Debt: ARGX had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARGX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ARGX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.